Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.